| 28.6 0.8 (2.88%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.05 |
1-year : | 39.78 |
| Resists | First : | 29.15 |
Second : | 34.05 |
| Pivot price | 25.65 |
|||
| Supports | First : | 22.88 |
Second : | 19 |
| MAs | MA(5) : | 27.23 |
MA(20) : | 24.88 |
| MA(100) : | 18.8 |
MA(250) : | 13.61 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 86 |
D(3) : | 83.4 |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 29.15 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SRZN ] has closed below upper band by 7.6%. Bollinger Bands are 34.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.2 - 29.3 | 29.3 - 29.39 |
| Low: | 27.22 - 27.35 | 27.35 - 27.46 |
| Close: | 28.4 - 28.61 | 28.61 - 28.77 |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Wed, 25 Feb 2026
Biotech targeting sight-threatening eye disease joins TD Cowen investor stage - Stock Titan
Mon, 23 Feb 2026
New Surrozen hire gets option to buy 3,070 shares at $24.53 - Stock Titan
Mon, 23 Feb 2026
SRZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fri, 13 Feb 2026
Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 1,093 Shares - MarketBeat
Tue, 03 Feb 2026
Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Purchases 4,355 Shares of Stock - MarketBeat
Sat, 31 Jan 2026
Surrozen announces routine board resignation with no disputes - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 1.77e+006 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 200 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.723e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 107.3 % |
| Return on Equity (ttm) | -33.5 % |
| Qtrly Rev. Growth | 3.6e+006 % |
| Gross Profit (p.s.) | -155.52 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.81379e+007 |
| Qtrly Earnings Growth | -17.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.06 |
| Dividend | 0 |
| Forward Dividend | 241380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|